<DOC>
	<DOCNO>NCT00174434</DOCNO>
	<brief_summary>This study evaluate safety SU011248 combination paclitaxel patient metastatic locally recurrent breast cancer receive chemotherapy treatment advance disease setting .</brief_summary>
	<brief_title>Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Breast cancer evidence unresectable , locally recurrent metastatic disease . Candidate treatment paclitaxel . Prior chemotherapy advance disease set . HER2 positive disease unless previously treat trastuzumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>